Bristol-Myers (BMY) Opdivo Trial Miss a 'Seismic Event', BMO Capital Says (MRK)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Piper Jaffray Cuts Bristol-Myers (BMY) PT, Raises Merck's (MRK) Following BMY's CM-026 Failure
August 8, 2016 6:37 AM EDTPiper Jaffray analyst Richard Purkiss lowered his price target on Neutral-rated Bristol-Myers Squibb Co. (NYSE: BMY) to $65.00 (from $69.00) following news Friday that its CheckMate-026 (CM-026) trial of Opdivo missed its primary endpoint in the treatment of PD-L1+ expressors (>5% PD-L1+,~55-60% of patients) in... More
Credit Suisse Upgrades Merck (MRK) to Outperform
August 8, 2016 6:22 AM EDTCredit Suisse upgraded Merck (NYSE: MRK) from Neutral to Outperform with a price target of $73.00 following news Friday that Bristol-Myers' CheckMate-026 (CM-026) Study for Opdivo in 1st line non-small cell lung cancer (NSCLC) missed its primary endpoint.
Analyst Vamil Divan commented, "Friday's... More
SunTrust Robinson Humphrey Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral
August 5, 2016 9:30 AM EDTSunTrust Robinson Humphrey downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Buy to Neutral with a price target of $68.00 (from $86.00).
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click... More
Bristol-Myers Squibb (BMY) Falls 22% After Shares Resume Trading
August 5, 2016 8:32 AM EDTBristol-Myers Squibb (NYSE: BMY) Falls 22% After Shares Resume Trading
... MoreMerck (MRK) Surges After Bristol-Myers Squibb's (BMY) CheckMate -026 Trial Fails
August 5, 2016 8:24 AM EDT(Updated)
Shares of Merck (NYSE: MRK) surged pre-market Friday after Bristol-Myers Squibb (NYSE: BMY) released disappointing results from CheckMate -026, phase 3 study of Opdivo for treatment of patients with NSCLC.
The study showed Opdivo did not meet trial... More
Bristol-Myers Squibb (BMY) Says CheckMate -026 Trial for Opdivo Missed Primary Endpoint
August 5, 2016 8:21 AM EDTBristol-Myers Squibb Company (NYSE: BMY) announced that CheckMate -026, a trial investigating the use of Opdivo (nivolumab) as monotherapy, did not meet its primary endpoint of progression-free survival in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 at 5%. The company will complete a full evaluation of the... More
